Literature DB >> 16134732

Pancytopenia induced by low-dose methotrexate. A study of the cases reported to the Finnish Adverse Drug Reaction Register From 1991 to 1999.

T Kuitunen1, J Malmström, E Palva, T Pettersson.   

Abstract

OBJECTIVE: To study cases of low-dose methotrexate-induced pancytopenia with special reference to clinical outcome and factors predisposing to bone marrow suppression.
METHODS: Patient files of 14 cases of methotrexate-induced pancytopenia reported to the National Agency for Medicines in Finland from 1991 to 1999 were reviewed. A review of four additional cases was included.
RESULTS: Of the 18 patients (median age 72 years), 12 had rheumatoid arthritis, one psoriatic arthritis, five psoriasis without arthritis, and one pemphigus erythematosus. Major co-morbidity was recorded in 12 patients, and 16 patients used significant concomitant drugs. Eight patients had a mildly or moderately elevated serum creatinine concentration. In every patient the occurrence of cytopenia was abrupt. Eight patients (44%) died, and the most frequent cause of death was infection.
CONCLUSIONS: Our data show that methotrexate-induced pancytopenia is associated with high mortality especially in cases with significant co-morbidity and concomitant medications.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16134732     DOI: 10.1080/03009740510018570

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  7 in total

1.  Low-dose methotrexate-induced pancytopenia.

Authors:  Yogesh Preet Singh; Amita Aggarwal; Ramnath Misra; Vikas Agarwal
Journal:  Clin Rheumatol       Date:  2006-04-25       Impact factor: 2.980

Review 2.  Neutropenia in the Elderly: A Rheumatology Perspective.

Authors:  Su-Ann Yeoh; Christine Fox; Richard Hull
Journal:  Drugs Aging       Date:  2016-08       Impact factor: 3.923

Review 3.  Optimizing perioperative outcomes for older patients with rheumatoid arthritis undergoing arthroplasty: emphasis on medication management.

Authors:  Susan M Goodman
Journal:  Drugs Aging       Date:  2015-05       Impact factor: 3.923

Review 4.  Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: a systematic literature review.

Authors:  Susan M Goodman; Bruce N Cronstein; Vivian P Bykerk
Journal:  Clin Exp Rheumatol       Date:  2014-12-23       Impact factor: 4.473

5.  Extracorporeal Treatment for Methotrexate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.

Authors:  Marc Ghannoum; Darren M Roberts; David S Goldfarb; Jesper Heldrup; Kurt Anseeuw; Tais F Galvao; Thomas D Nolin; Robert S Hoffman; Valery Lavergne; Paul Meyers; Sophie Gosselin; Tudor Botnaru; Karine Mardini; David M Wood
Journal:  Clin J Am Soc Nephrol       Date:  2022-03-02       Impact factor: 10.614

6.  Factors Associated with Myelosuppression Related to Low-Dose Methotrexate Therapy for Inflammatory Rheumatic Diseases.

Authors:  Shunsuke Mori; Michihiro Hidaka; Toshiro Kawakita; Toshihiko Hidaka; Hiroyuki Tsuda; Tamami Yoshitama; Kiyoshi Migita; Yukitaka Ueki
Journal:  PLoS One       Date:  2016-04-29       Impact factor: 3.240

7.  Methotrexate-Induced Pancytopenia and Mucositis Caused by Medication Error.

Authors:  Maame-Boatemaa Amissah-Arthur; Winifred Baah
Journal:  Ghana Med J       Date:  2020-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.